Kidney RSS News Feeds

Nephrology

sponsor

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Yener S et al. - The results showed that nonobese diabetic patients at low cardiovascular risk had similar levels of subclinical markers of inflammation and fibrinolysis as matched healthy controls. Neither metformin nor rosiglitazone caused marked changes in sCD40L, PAI-1 and TAFI antigen levels. A subset of patients who received simvastatin showed a modest decrease in PAI-1 level and could contribute to beneficial vasculoprotective effect of the drug in type 2 diabetics.

Related Articles

Acute Ingestion of Long-Chain (n-3) Polyunsaturated Fatty Acids Decreases Fibrinolysis in Men with Metabolic Syndrome
The Journal of Nutrition, 11/06/09    Relevance Score: 87%

Thrombin Activatable Fibrinolysis Inhibitor and Clot Lysis Time in Pregnant Patients with Antiphospholipid Syndrome: Relationship with Pregnancy Outcome and Thrombosis
American Journal of Reproductive Immunology, 11/13/09    Relevance Score: 83%

Long-Term Prognostic Value of ST-Segment Resolution in Patients Treated With Fibrinolysis or Primary Percutaneous Coronary Intervention
JACC - Journal of the American College of Cardiology, 11/02/09    Relevance Score: 83%

Elevated PAI-1 is associated with poor clinical outcomes in pediatric patients with acute lung injury
Intensive Care Medicine, 10/28/09    Relevance Score: 80%

Single-chain urokinase in empyema induced by pasturella multocida
Experimental Lung Research, 10/22/09    Relevance Score: 80%